Spruce Street Capital »

Relmada Therapeutics shares owned by Spruce Street Capital

Quarter-by-quarter ownership of Relmada Therapeutics (RLMD) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in Relmada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Relmada Therapeutics held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Relmada Therapeutics by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $44M 6.4M 6.92

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding Relmada Therapeutics

Henderson Group
Squadron Capital Management
Spruce Street Capital
VR Adviser
Adage Capital Partners GP
OrbiMed Advisors
Vanguard Capital Management
Millennium Management
RA Capital Management
Ikarian Capital
Marshall Wace
Driehaus Capital Management
Ameriprise Financial
Polar Capital Holdings
Susquehanna International

View all funds holding Relmada Therapeutics